Honasa Q1 FY27: consol PAT doubles YoY to ₹90 Cr as OPM jumps ~690bps to 14.6%
PAT +118.9% YoY · revenue +27% · margins expanding
₹755.95 Cr
+27% YoY
₹90.45 Cr
+118.9% YoY
11.62%
+4.9pp YoY
₹2.77
Consolidated revenue from operations rose 27.0% YoY to ₹755.9 Cr (₹595.3 Cr in Q1 FY26) and 15.0% QoQ from ₹657.1 Cr; PAT jumped 118.9% YoY to ₹90.4 Cr (₹41.3 Cr) and 30.3% QoQ (₹69.4 Cr), with basic EPS at ₹2.77 versus ₹1.27 a year ago and ₹2.13 last quarter. Neither the current nor the year-ago quarter carries an exceptional item, so the reported growth rate is also the clean underlying rate — profit growth comfortably outran revenue growth, the signal that makes this a margin-led beat rather than just a top-line story.
Q1 FY-2027 vs prior quarters
Operating margin (EBITDA/revenue-from-ops) expanded roughly 690 bps YoY to 14.58% (7.70% in Q1 FY26) and about 283 bps sequentially from 11.75%, while net margin widened to 11.62% of total income from 6.67% a year ago. The expansion tracks management's stated channel/brand-spend leverage playbook and clears the "double-digit operating margin" floor the company flagged ahead of results. Standalone (parent-only) PAT was ₹84.3 Cr on revenue of ₹696.3 Cr, up a slower 19.3% YoY — the gap versus consolidated's 27.0% points to subsidiaries and the JV (BBlunt salons, overseas units, BTM Ventures) growing faster than the parent book; readers comparing the two should note this divergence rather than treat either figure as the anomaly.
The stock went into the print at ₹479, up 1.8% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters.
Management is confident in delivering a high-teens CAGR over the next 5 years, with a target of 500 basis points EBITDA expansion during the same period. They anticipate continued strong growth from young brands and focus categories, with Mamaearth projected to achieve a double-digit CAGR over the next 5 years and expa
— This quarter: met
Against its own July 9, 2026 quarterly update, management had guided ~30% YoY underlying growth but explicitly flagged that reported-basis growth would land in the mid-20s because Flipkart changed its marketplace reporting convention, netting fulfilment/logistics costs before paying Honasa for goods sold. The actual 27.0% reported print sits inside that guided band, so this reads as a "met" on revenue, not a beat or a miss — margin came in ahead of the stated double-digit floor. No independent analyst PAT consensus for the quarter turned up in search, so the print cannot be graded against Street numbers; no separate management press-release commentary was available for this filing. On the legal front, the Dubai Cassation Court on July 29, 2026 upheld a ~₹4.3 Cr (AED1.75 mn) compensation order against Honasa in the RSM distributorship dispute, while a separately-seated Delhi arbitration tribunal (award dated May 14, amended June 26, 2026) went the other way, awarding Honasa ~₹25.5 Cr (AED9.92 mn) plus further damages from RSM — neither figure is booked in this quarter's P&L, since exceptional items are nil in both the current and comparative columns.
W1
Whether OPM (14.58% this quarter, +690bps YoY) sustains as revenue growth normalizes toward management's ~30% underlying target versus this quarter's mid-20s reported print.
W2
Cash recovery status of the ~₹25.5 Cr (AED9.92mn) Delhi arbitration award against RSM — not yet reflected in the balance sheet or P&L.
W3
Progress on the Fluence Pharma acquisition (58% stake, board-approved Jun 23, 2026) toward closing and first-quarter consolidation.
Clean typed statement, figures in Rs. Million converted to Cr (÷10); arithmetic checks exact for both standalone and consolidated. Consolidated PBT includes a ₹0.057 Cr share of JV profit; NCI is immaterial (PAT attributable to owners ₹90.249 Cr of ₹90.448 Cr total). No exceptional items in current or year-ago quarter columns (the ₹4.797 Cr labour-code exceptional charge sits only in the FY26 full-year column), so no adjusted-growth calc is needed.
Growth confirmed; Q2 headwinds flagged
Honasa delivered ₹756 Cr revenue (+27% YoY), beating the high-teens guidance target. Yet management maintained guidance rather than raising it. The call explains the measured stance — and where the real risk lies.
₹756 Cr
+27% YoY, +15% QoQ
₹90.4 Cr
+119% YoY, +30% QoQ
14.6%
target 15% in 5 years
30.5%
not price-driven
Honasa's Q1 was strong across the board — ₹756 Cr revenue beat the high-teens CAGR target, PAT more than doubled on margin expansion, and focus categories (face wash, sunscreen, hair care) drove 35% growth at 85% portfolio contribution. Yet on the call, management maintained its 5-year guidance rather than raising it. That gap — between the beat and the caution — is the story of the quarter.
Why the measured tone?
Management laid three flags. First: Q1 is seasonally strong. Face wash and sunscreen categories peak in summer, contributing ~50 basis points of EBITDA margin lift this quarter. Management expects Q2 to show sequential moderation as those categories fade. Second: cost inflation will bite harder in H2. Crude oil and packaging material inflation are real; the company absorbed the impact in Q1 through inventory management and took calibrated price increases at quarter-end. 'The real impact of it will be Q2,' CFO Ramanpreet Sohi warned. Third: younger brands have hit a ceiling. Aqualogica, BBlunt, Dr. Sheth's, and Reginald are all growing at 40%+ but are capped at ₹150–200 Cr annual run-rate. Management now acknowledges this is a repositioning challenge, not just a timing one.
Parsing management's claims
32% reported growth delivered
₹756 Cr YoY = 27% (Flipkart settlement-adjusted LTL reconciliation)
Slightly overstated
PAT of ₹90 crores
₹90.4 Cr reported
Supported
EBITDA margin expanding on path to 15%
14.6% (₹110 Cr EBITDA); 100–150bps annual expansion track record confirmed
Supported
Cost inflation managed, no margin deterioration
NPM 11.6%, volume-led growth (30.5%) shows demand strength, pricing modest
Supported
Derma Co reached ₹1000Cr ARR milestone
Confirmed; second ₹1000Cr brand in portfolio (Mamaearth core also ₹1000Cr+)
Supported
Mamaearth accelerated to high-teens growth
Core brand contribution not separately disclosed; 27% portfolio growth consistent with core beating average
Unverified but credible
What shifted on this call
Younger brands ceiling acknowledged. Prior roadmaps assumed continuous scale. Now Aqualogica, BBlunt, Dr. Sheth's, Reginald all sit at ₹150–200 Cr ARR despite 40%+ growth — management flagged repositioning needed to unlock next leg (GenZ relaunch for Aqualogica, refinements for BBlunt and Dr. Sheth's over 6–9 months).
Mamaearth trajectory upgraded in tone. High-teens growth delivered in Q1 (vs. prior double-digit CAGR baseline); Rice face wash now #1 in category, Rosemary shampoo >₹100 Cr ARR. Distribution gains across Modern Trade and General Trade signal share capture.
Fragrance strategy evolved post-failure. Mamaearth's prior fragrance attempt failed on poor product-market fit. The company learned and is now launching FIKN as a standalone brand, distinct from Mamaearth, with 1.5 years of R&D backing.
We finally have launched a brand called FIKN. It's India's first elixir-based brand, which is the highest dosed and the strongest form of perfume.
Fluence Pharma still in diligence. Nutraceuticals deal announced but has not closed; Honasa Health subsidiary created for strategic oversight, but integration timeline unproven.
The bull-bear ledger
Multi-brand portfolio scaling is real and credible (Derma Co ₹1000Cr, Mamaearth high-teens, focus categories 35% growth)
Distribution reach 300k+ outlets; GT secondary sales +40%, MT offtakes +40% show retail strength
Volume-driven growth (30.5%) and inventory discipline (<30 days distributor inventory) demonstrate operational health
EBITDA margin 14.6% on confirmed path to 15% via 100–150bps/year expansion
Q1 seasonally inflated; Q2 sequential dip expected, moderating near-term momentum
Younger brands hit ₹150–200Cr ceiling despite 40%+ growth; scaling past that requires execution
Cost inflation (crude, packaging) absorbed Q1 via inventory; Q2 margin pressure likely
FIKN fragrance early-stage; prior Mamaearth fragrance failed; market unproven
Risks, ranked by holder concern
Younger brand scaling ceiling at ₹150–200Cr ARR
MediumAqualogica, BBlunt, Dr. Sheth's all capped despite 40%+ growth. GenZ repositioning for Aqualogica and 6–9 month refinements for BBlunt/Dr. Sheth's must unlock next leg. If they don't, portfolio growth slows materially in FY28–FY29.
Cost inflation Q2 margin pressure
MediumCrude oil and packaging inflation real. Company absorbed Q1 via inventory; price increases calibrated end-Q1. H2 margin pressure likely. Target 100–150bps expansion may face headwinds if A&P inflation also accelerates.
Q2 seasonal dip and comp toughness
Low-MediumSummer categories peak Q1 (face wash, sunscreen). Q2 'sequentially dips a little.' 9-month CAGR comps also toughen post-strong H2 FY26 base. Growth deceleration expected.
FIKN fragrance execution
MediumNew category; prior Mamaearth fragrance failed on poor PMF. FIKN is standalone brand, India-first elixir claim, patented design — but market unproven. Success not assured at scale.
Fluence Pharma integration timing and uncertainty
LowNutraceuticals deal in diligence, not closed. Honasa Health subsidiary created but no timeline on completion or integration. Adds strategic optionality but no near-term earnings lift.
How the street is reading this
The stock popped +4.97% on day 1 post-result announcement (31.9% delivery), but the move faded by day 3 (−0.92%). That reversal tells a story: the market priced in the beat but got sceptical on the lack of guidance raise. It's now positioned at ₹476.1, up 91.67% from its 52-week low and just 6.61% off its all-time high. The trend is bullish (above SMA20, SMA50, SMA200), but RSI sits at 64.1 (neutral territory).
Ownership tells a nuanced story. FII are quietly selling (−10 basis points QoQ, down from 15.50% in Q2 FY26 to 13.64% now), but DII added 234 basis points this quarter (21.58% vs. 19.24% in Q4), suggesting domestic institutional confidence holding even as foreign money rotates. Promoters steady at 35.47%.
In bulk/block trades, the most significant move was Sofina Ventures (Unilever's VC arm, a major early Honasa investor) selling 41.78 lakh shares @ ₹424 on May 22, 2026. Sofina at ₹424 vs. stock now ₹476 signals a VC taking profits after the strong run-up, not a red flag on fundamentals. Other traders (Microcurves, QE Securities, NK Securities) also active in mid-May, suggesting typical position rebalancing.
1 · Younger brand repositioning traction (next 6–9 months)
Aqualogica GenZ relaunch, BBlunt and Dr. Sheth's refinements are the gating factors for ₹150–200Cr ceiling break. Watch Q2 and H1 numbers for each brand; if they remain capped despite marketing push, multi-brand portfolio growth slows.
2 · Q2 margin and cost inflation absorption
Q2 will show whether price increases taken end-Q1 offset crude and packaging inflation or margin compresses. Track EBITDA margin QoQ; anything below 14% signals execution risk to 15% target.
3 · FIKN fragrance early traction and Fluence Pharma closure
FIKN is India-first elixir-based claim; market response (trial, repeat, ASP) will show whether prior Mamaearth fragrance failure was a category or execution miss. Fluence diligence completion and integration roadmap clarity are secondary watch items.
Honasa's Q1 is a steady, credible quarter — not a step-change, but a confirmation that multi-brand portfolio scaling is real. Revenue beat guidance, margin expansion is on path, and retail distribution is strong. But the quarter also reveals constraints: Q1 is seasonal, Q2 will dip, younger brands have hit a ceiling, and cost inflation is coming.
Management's measured guidance stance is appropriate given these headwinds. The stock has run hard (91% off low, only 6% off ATH), and the pop-and-fade post-result (day 1 +5%, day 3 −0.9%) reflects a market that priced in the beat but is sceptical on acceleration.
The number to track from here is whether younger brands break their ₹150–200Cr ceiling. That's the key execution test. If GenZ repositioning for Aqualogica and refinements for BBlunt/Dr. Sheth's gain traction, multi-brand growth unlocks its next leg. If not, portfolio growth moderates materially into FY28. Margin expansion (14.6% → 15%) is achievable but will be pressure-tested by H2 cost inflation. Watch Q2 EBITDA margin closely — it's the organic health check.
Growth confirmed, Q2 headwinds flagged
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade A
Q1 beat revenue guidance (27% vs high-teens target). Derma Co ₹1000Cr milestone reached; BTM post-acquisition 100% growth validates inorganic playbook.
Optimistic
next 1–2 quarters
Optimistic
multi-year
₹756Cr revenue (+27% YoY) and ₹90Cr PAT (+119%) confirm multi-brand portfolio scaling on guidance trajectory; EBITDA margin (14.6%) on path to 15% via committed 100–150bps annual expansion. Key risk: Q2 seasonal headwind and younger brands capped below ₹200Cr ARR despite 40%+ growth.
₹755.9 Cr
Revenue · +27% YoY₹90.4 Cr
Reported PAT · +118.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
32% reported growth delivered
OVERSTATED27% YoY revenue growth (Flipkart settlement-adjusted LTL reconciliation)
PAT of INR90 crores
METINR90.4 crores reported
EBITDA margin expanding, on path to 15%
MET14.6% EBITDA margin (₹110Cr); track record shows 100–150bps annual expansion target
Cost inflation managed via inventory and pricing
METNPM 11.6%, no visible margin deterioration despite sector-wide crude/packaging inflation
Mamaearth accelerated to high-teens growth
UnverifiedCore brand contribution not separately disclosed; 27% portfolio growth consistent with core exceeding average
Earnings quality
What changed since the last call
FY27 growth guidance upgraded in tone
UpgradeManagement flagged FY27 will exceed high-teens CAGR (prior maintained at high-teens). Q1 27% validates upside; full year expected to beat range.
Mamaearth trajectory strengthening
UpgradeMamaearth achieving high-teens growth (prior: double-digit CAGR commitment). Rice, Rosemary, Sun Care categories accelerating; hero SKU strategy delivering.
EBITDA margin path reaffirmed, on-track
Neutral14.6% EBITDA margin; 100–150bps/year expansion confirmed to 15% in 5 years. FY27 seen at 150–200bps (above average) due to operating leverage and mix.
Younger brands acknowledge ceiling at ₹150–200Cr
DowngradeAqualogica, BBlunt, Dr. Sheth's, Reginald all plateauing despite 40%+ growth. Prior roadmap assumed continuous scale; now repositioning required to unlock next leg.
Fragrance category strategy refined post-failure
NeutralMamaearth's prior fragrance attempt discontinued (poor PMF). Learned fragrance-first approach essential; now FIKN launched standalone, gender-specific, elixir-based (India-first).
The Q&A
Analysts pressed on comp toughness, inventory build-up, younger brand scaling, cost inflation. Management held firm with data (distributor inventory <30 days, price increases taken Q1), acknowledged Q2 seasonal dip, defended growth-first stance. Transparent without over-committing on proprietary details.
Growth outlook & comps — Vivek M, Jefferies
AnsweredHigh-teens CAGR target maintained. This year will be better than planned CAGR. Distribution gains driving outlook.
Mamaearth trajectory — Vivek M, Jefferies
AnsweredDouble-digit CAGR reaffirmed. FY27 expected to exceed planned growth profile. Inputs (distribution, product mix) supporting target.
Quick commerce share — Vivek M, Jefferies
AnsweredCategory-level unaudited data (e.g., face wash, sunscreen share). QC is branded purchase; strong brands gain via consumer searches. Pareto will dominate.
Younger brand scaling — Vidisha Sheth, Ambit
AnsweredDifferentiated proposition → focus → share gain. Aqualogica GenZ relaunch done; BBlunt, Dr. Sheth's actions planned over 6–9 months. Each brand different strategy.
Margin trade-off with growth — Vidisha Sheth, Ambit
AnsweredInvestor day plan assumes growth prioritization. Core will grow and profitabilize, funding new brands/categories while delivering committed 4–5yr goals.
Inventory health in GT/MT — Aditya Soman, CLSA
AnsweredTracking distributor inventories real-time. <30 days now. Collections at highest ever. Retail STRs healthier than category. Extremely confident.
Derma Co offline journey — Jay Doshi, Kotak
Answered₹3lakh is AC Nielsen universe; Mamaearth driving expansion. Derma Co ~1yr into offline, 50k GT outlets, 80% online 20% offline contribution.
Fluence Pharma strategy — Jay Doshi, Kotak
PartialHonasa Health subsidiary created. Fluence in condition precedent/diligence. Nutrition/wellness as decadal opportunity. Organic propositions also planned.
Mamaearth new product pipeline — Jay Doshi, Kotak
AnsweredRice can be ₹500Cr franchise. Rosemary ₹250Cr+ next year. Moisturizers at ₹50Cr, Vitamin C sunscreen next ₹100Cr candidate. New partitions (acne, dandruff) future ₹100Cr+.
Fragrance market entry & learning — Umang Shah, Banyan Tree
AnsweredMamaearth's early fragrance lacked consumer PMF, shut down. Learned fragrance-first approach essential. Spent 1.5 years building R&D. FIKN now launched standalone, gender-specific, elixir-based.
E-commerce channel breakdown — Umang Shah, Banyan Tree
DodgedUsually don't give channel-level breakdowns.
Cost inflation offset — Nitin Shakdher, Green Capital
AnsweredCrude and packaging inflation real. Good inventory management in Q1 absorbed impact. Price increases taken end-Q1. Real impact hits Q2.
Gen Z demand trend — Nitin, HDFC Securities
AnsweredGen Z becoming 45% buying cohort in B2C e-commerce. Aqualogica sharply focused there. Confident in brand sharpness + TG relevance.
Mamaearth channel balance — Jay Doshi, Kotak
AnsweredBoth strong double-digits.
Guidance
High-teens CAGR over 5 years
HighQ1 27% beats range. FY27 expected to exceed high-teens CAGR. Multi-brand acceleration tracking.
15% EBITDA margin in 5 years via 100–150bps annual expansion
HighCurrently 14.6%. FY27 seen at 150–200bps expansion (above average). Operating leverage + mix driving path.
Mamaearth double-digit CAGR maintained
HighQ1 high-teens growth achieved. Distribution gains, hero SKU focus, share gains (face wash +350bps, shampoo +160bps).
Risks the call surfaced
Younger brand scaling
MediumAqualogica, BBlunt, Dr. Sheth's plateau at ₹150–200Cr ARR despite 40%+ growth. Category/TG limitations or positioning gaps slow ascent to ₹500Cr+.
Q2 seasonality headwind
LowSummer categories (face wash, sunscreen) peak Q1, contributing ~50bps EBITDA seasonality. Q2 'sequentially the scale kind of dips a little' as summer fades.
Cost inflation absorption
MediumCrude oil inflation (West Asia war), packaging material inflation impacting industry. Q1 absorbed via inventory management; real impact shifts to Q2. Price increases taken end-Q1 may not fully offset.
New category execution risk
MediumFIKN fragrance just launched (India-first elixir-based claim, patented design). Prior Mamaearth fragrance attempt failed (poor PMF). Fluence Pharma diligence ongoing; nutraceuticals execution unproven.
Acquisition integration
LowBTM Ventures 100% growth post-acquisition (Jan 2026) impressive, but sustainability uncertain. Fluence Pharma deal in diligence; completion and integration timeline unclear.
Management
Score 8/10. Direct and data-backed. Acknowledged challenges (younger brand ceiling, cost inflation, prior fragrance failure). Selective on proprietary details (reasonable competitive sensitivity). Transparent on Q2 headwinds. Track record strong: hit revenue target (27% vs high-teens), Mamaearth high-teens delivered, EBITDA margin expansion on path. Younger brands scaled to ₹150–200Cr but face headroom limits. BTM acquisition 100% growth validates inorganic playbook.
1 · Q2 FY27
Younger brands repositioning results (Aqualogica GenZ, BBlunt, Dr. Sheth's improvements)
2 · H2 FY27
Product milestones: Rice ₹500Cr franchise, Rosemary ₹250Cr+ ARR targets
3 · H2 FY27
FIKN fragrance scaling trajectory; category expansion tracking
Key risk: Q2 seasonal headwind and younger brands capped below ₹200Cr ARR despite 40%+ growth.
Growth on Guidance, Margins the Test
Honasa enters Q1 FY27 results day projecting 30% revenue growth and double-digit operating margins—Street is cautiously bullish, but execution on Fluence integration and offline scaling will determine if the stock justifies its 92% run from 52-week lows.
The Setup: Growth Engine on Test
Honasa reports Q1 FY27 results on August 13 riding a surge that has lifted the stock 92% from its 52-week low. The narrative is straightforward: 30% revenue growth (unadjusted; mid-20s on reported basis after Flipkart policy shifts), sustained double-digit operating margins, and a strategic pivot into wellness via the Fluence Pharma acquisition (58% stake for ₹135 crore). But Street consensus is cautiously bullish—the stock has run, valuation concerns linger, and the real test is whether management can deliver margin expansion while scaling faster than peers. Miss on guidance or stumble on Fluence integration, and the re-rating narrative reverses.
~30%
Management guided for strong Q1 growth; mid-20s on reported basis (Flipkart policy adjustment)
~double-digit
Honasa committed to maintaining double-digit operating margins; offline expansion is key lever
~24–25%
Analyst consensus for FY27; dependent on Q1 execution setting the tone
high-teens growth
Core growth engine; younger portfolio brands (Derma Co, Aqualogica, etc.) tracking early 40s
On Track? The Prior Trajectory
Honasa closed FY26 with ₹200 crore PAT (double-digit growth trajectory), Q4 FY26 revenue at ₹682 Cr (28% YoY growth), and EBITDA at ₹77 Cr—a foundation of momentum. The company has signaled confidence in FY27 earnings growth of 24–25% and articulated a long-term goal of doubling EBITDA margins over FY24–30. Q1 FY27, if it delivers 30% revenue growth at sustained margins, would set a healthy baseline for that ambition. The wildcard: Fluence integration and whether the nutraceuticals addition dilutes or accels overall margin profile (initial market reaction was mixed: stock fell 4% on deal announcement, though analysts support the strategic diversification).
What the Street Says
Since Last Quarter: The Event Scan
1 · Fluence Pharma Acquisition (Jun 23, 2026)
Honasa acquired 58% stake in science-backed nutraceuticals company for ~₹135 Cr. Strategic entry into India's ₹16,000+ Cr wellness market. Initial market reception mixed (stock fell 4% on deal news), but analysts support the portfolio diversification. Integration timeline and margin accretion are key watches; Street expects positive synergies with derma portfolio (The Derma Co, Aqualogica).
2 · CMO Appointment (Aug 6, 2026)
Nilesh Kotalwar elevated from SVP–Online Revenue to Chief Marketing Officer, effective Aug 6. Signals focus on brand-building and positioning ahead of reported results. Limited material impact on Q1 earnings, but demonstrates continued leadership investment.
3 · FY26 Dividend & Subsidiary Move (May–Jul 2026)
Board recommended maiden final dividend of ₹3 per share (30% payout) for FY26. Honasa Health Private Limited incorporated as wholly owned subsidiary on Jul 7, 2026—preparation for potential health/wellness vertical expansion (synergistic with Fluence). Insurance Trading window closed from Jul 1 until 48 hrs after Q1 result submission.
4 · Arbitration Win Rectified (Jun 26, 2026)
Honasa won rectification order in arbitration vs. RSMM General Trading LLC; award increased to AED 9.9M (~₹21 Cr). Initial award was ₹18.88 Cr. Non-cash item, but demonstrates successful dispute resolution and potential future collectible. Routine governance and risk management.
What to Watch on Result Day
1 · Revenue Growth Confirmation
Is Honasa tracking the 30% YoY growth (unadjusted) it guided for? Peel the onion: Mamaearth (high-teens growth), younger brands (Derma Co, Aqualogica, BBlunt, Dr. Sheth's—early 40s), and offline expansion metrics (outlet count, distribution %). Any shortfall here resets growth narrative and invites re-rating pressure.
2 · Operating Margin Trajectory
Did Honasa sustain double-digit operating margins despite higher inflation/logistics costs? This is where execution on offline scaling (target 400k+ retail outlets) and operational leverage matter most. If margins compress, Street will question the long-term 2x EBITDA-margin ambition. If margins are stable or expand, bulls have the narrative.
3 · Fluence Pharma Integration Clarity
Any early commentary on nutraceuticals ramp, distribution strategy, or expected contribution to FY27 PAT? Management will likely provide a timeline for profitability and margin contribution. Street is watching for execution risk; a credible plan de-risks the initial negative reaction.
Honasa enters Q1 FY27 results with a strong growth narrative (30% revenue, 24–25% PAT) and a strategic acquisition that diversifies beyond D2C beauty into wellness. The stock has priced in this optimism, up 92% from the 52-week low. Street consensus is bullish, but valuation discipline is intact—the print must deliver on guidance. Watch revenue confirmation, margin sustainability, and early Fluence signals. A beat could push the Jefferies bull case (₹610); a miss invites sharp compression. This is an execution quarter.